Page last updated: 2024-12-06

siratiazem

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Siratiazem is a novel calcium channel blocker that was initially developed for the treatment of cardiovascular diseases. It was synthesized by a team of researchers at the University of California, San Francisco, and its effects on heart function were extensively studied. Siratiazem exhibits vasodilatory properties, relaxing blood vessels and reducing blood pressure. It is also known to reduce heart rate and contractility, contributing to its potential therapeutic benefits for conditions such as hypertension, angina pectoris, and arrhythmias. The unique pharmacological profile of Siratiazem made it a subject of extensive research to explore its potential therapeutic applications. Its ability to target calcium channels, which play a crucial role in regulating various physiological processes, has led to investigations into its potential uses beyond cardiovascular diseases, including neuroprotective effects and its role in cancer treatment.'

siratiazem: RN refers to (2S-cis)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65989
CHEMBL ID2107305
SCHEMBL ID1936297
MeSH IDM0226147

Synonyms (12)

Synonym
siratiazem
[(2s,3s)-2-(4-methoxyphenyl)-5-[2-[methyl(propan-2-yl)amino]ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate
chj1x6ag9f ,
(+)-(2s,3s)-2,3-dihydro-3-hydroxy-5-(2-(isopropylmethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5h)-one acetate (ester)
unii-chj1x6ag9f
1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methyl(1-methylethyl)amino)ethyl)-, cis-(+)-
siratiazem [inn]
138778-28-6
CHEMBL2107305
SCHEMBL1936297
[(2s,3s)-2-(4-methoxyphenyl)-5-[2-[methyl(propan-2-yl)amino]ethyl]-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl]acetate
Q27275467

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Half-life of elimination of diltiazem was significantly shorter than that of LR-A/113, both after oral (37 +/- 9 vs 59 +/- 26 min) and intravenous (29 +/- 12 vs 57 +/- 16 min) administration."( Pharmacokinetics of diltiazem and a new analogue, LR-A/113, in the conscious rat.
Bernasconi, R; Caliari, S; Latini, R; Leopaldi, D; Porzio, S; Salimbeni, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]